Double-Blind Naltrexone in Compulsive Sexual Behavior - NCT00467558-55454 (Clinical Trial 169199)


Welcome To Clinical Connection



Our clinical trials database is updated daily
Over 250,000 individuals are currently being connected to clinical trials by ClinicalConnection.com!


Trials Alerts	Trials Search
Health Forum	Health News
RSS	Intro
Clinics & Sponsors	Member Login

View Clinical Trial (Medical Research Study)

Double-Blind Naltrexone in Compulsive Sexual Behavior - NCT00467558-55454 (Clinical Trial 169199)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy169199.aspx

** Please review additional "Nearby Studies" on right ----->

City:

Minneapolis

State:

Zip Code:

55454

Conditions:

Compulsive Sexual Behavior

Purpose:

The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in compulsive sexual behavior. Twenty subjects with DSM-IV compulsive sexual behavior will receive 8 weeks of naltrexone or placebo. The hypothesis to be tested is that naltrexone will be effective in reducing the urges to act out sexually in patients with compulsive sexual behavior. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Study summary:

The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 20 subjects with compulsive sexual behavior.

Criteria:

Inclusion Criteria: 1. men and women age 21-75; 2. current diagnosis of compulsive sexual behavior Exclusion Criteria: 1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination; 2. history of seizures; 3. myocardial infarction within 6 months; 4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential; 5. clinically significant suicidality; 6. current or recent (past 1 month) DSM-IV substance abuse or dependence; 7. illegal substance within 2 weeks of study initiation; 8. initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline; 9. initiation of a psychotropic medication within 2 months prior to study inclusion; 10. previous treatment with naltrexone; and 11. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

Study is available at:

University of Minnesota
Minneapolis, MN 55454
United States

Primary Contact:
Brian L Odlaug
Email: odla0019@umn.edu
Phone: 612-627-4363

Secondary Contact:
Brian L Odlaug
Email: odla0019@umn.edu
Phone: 612-627-4363

If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.

Trials Alerts:

If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source:		ClinicalTrials.gov
Date Processed:		March 15, 2010
Modifications to this listing:		Only selected fields are shown, please use the link above to view all information about this clinical trial.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.


Featured Nearby Studies:

Within 25 Miles

Diabetic Gastroparesis - Plymouth MN

Within 50 Miles

Within 100 Miles


Clinical Trials Search

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted nationwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.